Traws Pharma Statistics
Total Valuation
Traws Pharma has a market cap or net worth of $20.76 million. The enterprise value is $17.62 million.
| Market Cap | 20.76M |
| Enterprise Value | 17.62M |
Important Dates
The last earnings date was Friday, May 15, 2026, before market open.
| Earnings Date | May 15, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Traws Pharma has 15.15 million shares outstanding. The number of shares has increased by 196.62% in one year.
| Current Share Class | 15.15M |
| Shares Outstanding | 15.15M |
| Shares Change (YoY) | +196.62% |
| Shares Change (QoQ) | +13.70% |
| Owned by Insiders (%) | 5.48% |
| Owned by Institutions (%) | 29.25% |
| Float | 11.73M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.59 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 6.45 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.43
| Current Ratio | 0.43 |
| Quick Ratio | 0.36 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -5,639.19% and return on invested capital (ROIC) is -3,559.14%.
| Return on Equity (ROE) | -5,639.19% |
| Return on Assets (ROA) | -90.09% |
| Return on Invested Capital (ROIC) | -3,559.14% |
| Return on Capital Employed (ROCE) | 388.32% |
| Weighted Average Cost of Capital (WACC) | 12.23% |
| Revenue Per Employee | $390,429 |
| Profits Per Employee | -$1.99M |
| Employee Count | 7 |
| Asset Turnover | 0.20 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -20.35% in the last 52 weeks. The beta is 1.45, so Traws Pharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.45 |
| 52-Week Price Change | -20.35% |
| 50-Day Moving Average | 1.54 |
| 200-Day Moving Average | 1.89 |
| Relative Strength Index (RSI) | 42.03 |
| Average Volume (20 Days) | 6,504,915 |
Short Selling Information
The latest short interest is 1.67 million, so 11.03% of the outstanding shares have been sold short.
| Short Interest | 1.67M |
| Short Previous Month | 560,036 |
| Short % of Shares Out | 11.03% |
| Short % of Float | 14.25% |
| Short Ratio (days to cover) | 0.30 |
Income Statement
In the last 12 months, Traws Pharma had revenue of $2.73 million and -$13.91 million in losses. Loss per share was -$1.52.
| Revenue | 2.73M |
| Gross Profit | 2.73M |
| Operating Income | -19.62M |
| Pretax Income | -19.43M |
| Net Income | -13.91M |
| EBITDA | -19.51M |
| EBIT | -19.62M |
| Loss Per Share | -$1.52 |
Balance Sheet
The company has $3.13 million in cash and n/a in debt, with a net cash position of $3.13 million or $0.21 per share.
| Cash & Cash Equivalents | 3.13M |
| Total Debt | n/a |
| Net Cash | 3.13M |
| Net Cash Per Share | $0.21 |
| Equity (Book Value) | -5.31M |
| Book Value Per Share | -0.52 |
| Working Capital | -7.54M |
Cash Flow
| Operating Cash Flow | -15.32M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 104,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -15.32M |
| FCF Per Share | -$1.01 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -717.82% |
| Pretax Margin | -710.83% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Traws Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -196.62% |
| Shareholder Yield | -196.62% |
| Earnings Yield | -67.02% |
| FCF Yield | -73.83% |
Analyst Forecast
The average price target for Traws Pharma is $7.25, which is 429.20% higher than the current price. The consensus rating is "Buy".
| Price Target | $7.25 |
| Price Target Difference | 429.20% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 170.79% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on September 23, 2024. It was a reverse split with a ratio of 1:25.
| Last Split Date | Sep 23, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:25 |
Scores
Traws Pharma has an Altman Z-Score of -119.22 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -119.22 |
| Piotroski F-Score | 1 |